AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2200997
Drug: Cefazoline 3
RxNorm normalized name: cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazoline 3 g perioperatively
Trial: 25995313
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg)
Trial: 30322973
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of fentanyl: 1 mcg/kg loading dose followed by 1 mcg/kg/hour infusion
Trial: 30322973
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus (IB) doses of fentanyl: 1 mcg/kg/dose every 4 hours
Trial: 25648989
Drug: l-NMMA infusion
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NMMA infusion
Trial: 25648989
Drug: TEA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA infusion
Trial: 25648989
Drug: l-NMMA +
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NMMA + TEA infusion
Trial: 24953015
Drug: Extrafine beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID
Trial: 24953015
Drug: FOR 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOR 12 μg pMDI, 1 inhalation BID
Trial: 22928824
Drug: Gua Sha
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gua Sha therapy (single treatment)
Trial: 793848
Drug: Metoprolol 75
RxNorm normalized name: metoprolol 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 75 mg daily (increased to 450 mg max)
Trial: 793848
Drug: Alpha-methyldopa 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-methyldopa 375 mg daily (increased to 2250 mg max)
Trial: 21838410
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg once daily (after starting dose of 30 mg QD for 1 week)
Trial: 19647467
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin, administered twice a day for 36 months
Trial: 9806254
Drug: 5 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg triptorelin acetate s.c. daily
Trial: 9806254
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg triptorelin acetate s.c. daily
Trial: 9806254
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg triptorelin acetate s.c. daily
Trial: 9806254
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg triptorelin acetate s.c. daily
Trial: 871198
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml 4% lignocaine spray
Trial: 30267738
Drug: RNase1 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RNase1 treatment (pre-treated with RNase1 24 hours before A. hydrophila injection)
Trial: 25500425
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (OCA) 10 mg, 25 mg, or 50 mg once daily for 3 months
Trial: 21975193
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) plus treatment as usual (TAU)
Trial: 19291747
Drug: 1540 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1540 nm fractional laser treatments (three monthly treatments)
Trial: 16904063
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy package for generalized anxiety disorder (GAD)
Trial: 11239729
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment condition
Trial: 15151713
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of human menopausal gonadotrophin (HMG) by 75 IU on the day of antagonist administration (Group B)
Trial: 15151713
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of human menopausal gonadotrophin (HMG) (Group A)
Trial: 10654498
Drug: Heparin‐coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐coated circuit with silicone‐coated oxygenator (Group A)
Trial: 10654498
Drug: Whole heparin‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole heparin‐coated circuit (Group B)
Trial: 8161673
Drug: PEG‐ELS 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐ELS 4 L plus simethicone 120 mg
Trial: 8161673
Drug: PEG‐ELS 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐ELS 4 L plus placebo
Trial: 2868339
Drug: UKALL VIII
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UKALL VIII treatment regimen including continuous therapy during induction, long course of intramuscular asparaginase over 3 weeks, full-dose mercaptopurine and co-trimoxazole during CNS prophylaxis, sustained maximum tolerated doses of mercaptopurine and methotrexate maintenance.
Trial: 2868339
Drug: UKALL VII
RxNorm normalized name: factor VII
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UKALL VII treatment regimen for good-prognosis patients.
Trial: 2582828
Drug: MDI-spacer (0.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-spacer (0.36 mg of albuterol)
Trial: 2582828
Drug: Nebulizer (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer (2.5 mg of albuterol)
Trial: 23017611
Drug: Avoiding life-sustaining
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoiding life-sustaining therapies
Trial: 14964743
Drug: Topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil cream (0.5% 5-fluorouracil in a microsphere vehicle)
Trial: 2687008
Drug: Salbutamol controlled-release
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol controlled-release (SCR) 4 mg
Trial: 2687008
Drug: Salbutamol controlled-release
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol controlled-release (SCR) 8 mg
Trial: 1103400
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of streptomycin, isoniazid, and pyrazinamide
Trial: 1103400
Drug: 3 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times weekly regimen of streptomycin, isoniazid, and pyrazinamide
Trial: 1103400
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly regimen of streptomycin, isoniazid, and pyrazinamide
Trial: 1103400
Drug: Overall relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall relapse rates after 6 months' chemotherapy
Trial: 1103400
Drug: Overall relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall relapse rates after 9 months' chemotherapy
Trial: 28643323
Drug: Early intensified
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intensified protocol of six cycles of CHOP-14 with dose-dense rituximab and high-dose methotrexate
Trial: 28643323
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles R-CHOP-21 followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT)
Trial: 20689320
Drug: Vitamin K₂
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K₂ (menatetrenone) 45 mg/day for 1 year
Trial: 17084786
Drug: Treatment condition,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment condition, session sequence, and session date
Trial: 15643481
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (SH) injection (2 ml, Hyalgan, 20 mg/2 ml; once a week for 5 weeks)
Trial: 15643481
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution (once a week for 3 weeks)
Trial: 2971582
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide/2% miconazole cream (BPO-MCZ)
Trial: 2971582
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide gel (BPO)
Trial: 31473172
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 8 weeks (2q8)
Trial: 26832658
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 4 weeks (2q4)
Trial: 23208967
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen 30 minutes prior to the operation (group 50/0)
Trial: 23208967
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen 30 minutes after the operation (group 0/50)
Trial: 23208967
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dexketoprofen both 30 minutes prior and 30 minutes after the operation (group 25/25)
Trial: 19997572
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy for four weeks
Trial: 9694028
Drug: Methysergide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methysergide (2 mg)
Trial: 3071459
Drug: Ketanserin 10
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 10 to 30 mg twice daily
Trial: 3071459
Drug: Propranolol 20
RxNorm normalized name: propranolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 20 to 40 mg 3 times daily
Trial: 31050660
Drug: GR mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GR mirror therapy
Trial: 31050660
Drug: Conventional mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional mirror therapy
Trial: 31006282
Drug: Hourly titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly titrated oral misoprostol
Trial: 23999422
Drug: Dinoprostone 10
RxNorm normalized name: dinoprostone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone 10 mg vaginal insert
Trial: 22094327
Drug: EBRT dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT dose of 70.2 Gy
Trial: 22094327
Drug: EBRT dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT dose of 79.2 Gy
Trial: 15922815
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg/Ibuprofen 400 mg
Trial: 15922815
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg/Acetaminophen 325 mg
Trial: 15922815
Drug: Hydrocodone 7.5
RxNorm normalized name: HYDROCODONE 7.5/IBUPROFEN 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone 7.5 mg/Acetaminophen 500 mg
Trial: 12533165
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (Dysport, 100 U dissolved in 0.9% sodium chloride solution)
Trial: 8646728
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.)
Trial: 8646728
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.) + Lonidamine (75 mg orally three times on Day 1 to 150 mg orally three times on Day 7+)
Trial: 29765102
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral CBD
Trial: 17882808
Drug: Mildronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildronate (1 g/day) in addition to basic therapy
Trial: 15635344
Drug: Plant sterols/stanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols/stanols (2 g/day) incorporated into margarine (25 g/day)
Trial: 1092514
Drug: Theophylline (7.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (7.3 mg/kg per dose administered every 6 hr)
Trial: 1092514
Drug: Ephedrine (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (alone or in combination with theophylline and hydroxyzine)
Trial: 30773497
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg daily
Trial: 22882740
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (1.53 g EPA and 0.31 g DHA per 1000 kcal ME)
Trial: 22882740
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil supplementation (0.00 g EPA and 0.00 g DHA per 1000 kcal ME)
Trial: 11061244
Drug: Anticonvulsant sodium
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant sodium channel blockers
Trial: 11061244
Drug: Gabapentin (anticonvulsant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (anticonvulsant calcium channel blocker)
Trial: 11061244
Drug: Tramadol (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (mixed opioid and monoaminergic drug)
Trial: 11061244
Drug: Dextromethorphan (NMDA-antagonist)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (NMDA-antagonist)
Trial: 11061244
Drug: Mexiletine (antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (antiarrhythmic sodium channel blocker)
Trial: 8356370
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment with steroid injections
Trial: 8356370
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (standardized conventional but optimized activating treatment)
Trial: 29665493
Drug: Daily positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily positive events
Trial: 29665493
Drug: Daily stressful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stressful events
Trial: 27316778
Drug: 1% Tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Tenofovir Gel
Trial: 25190226
Drug: Alogliptin and
RxNorm normalized name: Alogliptin and Pioglitazone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin and insulin
Trial: 25190226
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and insulin
Trial: 21308859
Drug: 6-day residential
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-day residential course of lectures, discussions and peer groups on issues related to treatment and living with cancer
Trial: 16424293
Drug: Oxandrolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (10 mg twice daily)
Trial: 12001541
Drug: Intravenous heparin/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin/oral phenprocoumon
Trial: 31952249
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement containing Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, and a galactooligosaccharide mixture; duration: 3 months.
Trial: 31952249
Drug: Synbiotic supplement;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement;
Trial: 29941151
Drug: ZX008 (fenfluramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg after a 10-hour overnight fast
Trial: 29941151
Drug: ZX008 (fenfluramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg 30 minutes after a high-fat breakfast
Trial: 25756831
Drug: FDC aclidinium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC)
Trial: 25756831
Drug: FDC aclidinium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC)
Trial: 19723906
Drug: DMARD adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD adherence measured by Medication Adherence Scale (MARS)
Trial: 19723906
Drug: Disease duration,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease duration, perceived side-effects, beliefs about necessity of medicine
Trial: 17703139
Drug: Furosemide or
RxNorm normalized name: furosemide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide or HCTZ administered alone
Trial: 15385638
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium intake (<5 g/day)
Trial: 15385638
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (100 mg/kg/day)
Trial: 7886394
Drug: Omeprazole plus
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole plus amoxicillin (40 mg or 80 mg) for 1- or 2-week regimens
Trial: 7886394
Drug: Omeprazole plus
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole plus amoxicillin
Trial: 20090337
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg) once daily for 6-8 weeks before H. pylori eradication (group A)
Trial: 20090337
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment followed by lansoprazole (30 mg) for 6-8 weeks (group B)
Trial: 18381181
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg by mouth, 3 times per day for 4 weeks)
Trial: 10393676
Drug: Aspirin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250 mg/d)
Trial: 26538208
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg daily for 8 weeks
Trial: 19190916
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg hyoscine N‐butylbromide (HBB)
Trial: 2666139
Drug: SR‐Nicardipine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR‐Nicardipine 40 mg b.d.
Trial: 29548285
Drug: Pf-PQ1 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pf-PQ1 (0.25 mg/kg primaquine)
Trial: 29548285
Drug: Pv-PQ14 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pv-PQ14 (14 days unsupervised 3.5 mg/kg primaquine)
Trial: 27815344
Drug: SVG-DES (Drug-Eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVG-DES (Drug-Eluting Stents)
Trial: 20297945
Drug: Disulfiram 800
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 800 mg twice a week for 26 weeks
Trial: 18355302
Drug: Gender, absolute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender, absolute levodopa dose, weight, disease duration, and initial motor Unified Parkinson's disease rating score
Trial: 1521875
Drug: Prednisolone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.8 mg/kg
Trial: 29584548
Drug: Obinutuzumab (GA101)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (GA101) plus Bendamustine (B); G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2/d (days 1 and 2, all cycles); G maintenance (1,000 mg every 2 months) for up to 2 years.
Trial: 29584548
Drug: Bendamustine monotherapy;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine monotherapy; B 120 mg/m2/d.
Trial: 24417786
Drug: CG100649 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG100649 6 mg
Trial: 24417786
Drug: CG100649 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG100649 6 mg + ketoconazole 400 mg
Trial: 23046564
Drug: 2.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/day of n-3 PUFA for 8 weeks
Trial: 17141978
Drug: Subcutaneous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous amifostine 500 mg (two 250-mg injections) before radiation therapy